Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.
Study Goal
The researchers aimed to compare the acute psychoactive, autonomic, and endocrine effects of MDAI with those of MDMA (75 mg and 125 mg) in healthy volunteers.
Results Summary
MDAI produced subjective effects similar to 125 mg MDMA, increased blood pressure comparably, but did not elevate heart rate or body temperature. It also increased cortisol and prolactin levels and was detectable in serum and urine for several days.
Population
Six healthy volunteers (four males, two females).
Effective Dosage
MDMA doses of 75 mg and 125 mg were compared to MDAI (3.0 mg/kg, range 180-228 mg).
Duration
Acute effects were measured post-ingestion; MDAI remained detectable for at least 4 days in serum and 6 days in urine.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
MDAI (5,6-methylenedioxy-2-aminoindane) | no change | tolerability | six healthy volunteers (four males, two females) | - | was well tolerated | #1 |
MDAI (5,6-methylenedioxy-2-aminoindane) | increase | subjective effects | six healthy volunteers (four males, two females) | - | produced subjective effects comparable with those of 125 mg MDMA | #2 |
MDAI (5,6-methylenedioxy-2-aminoindane) | increase | blood pressure | six healthy volunteers (four males, two females) | - | increased blood pressure similar to 125 mg MDMA | #3 |
MDAI (5,6-methylenedioxy-2-aminoindane) | no change | heart rate | six healthy volunteers (four males, two females) | - | did not increase heart rate | #4 |
MDAI (5,6-methylenedioxy-2-aminoindane) | no change | body temperature | six healthy volunteers (four males, two females) | - | did not increase body temperature | #5 |
MDAI (5,6-methylenedioxy-2-aminoindane) | increase | cortisol levels | six healthy volunteers (four males, two females) | - | increased cortisol levels | #6 |
MDAI (5,6-methylenedioxy-2-aminoindane) | increase | prolactin levels | six healthy volunteers (four males, two females) | - | increased prolactin levels | #7 |
MDAI (5,6-methylenedioxy-2-aminoindane) | increase | serum detection | six healthy volunteers (four males, two females) | about 20 min | could be detected in serum about 20 min post ingestion | #8 |
MDAI (5,6-methylenedioxy-2-aminoindane) | no change | serum detection | six healthy volunteers (four males, two females) | at least for 4 days | remained detectable at least for 4 days | #9 |
MDAI (5,6-methylenedioxy-2-aminoindane) | no change | urine detection | six healthy volunteers (four males, two females) | at least 6 days | was detectable over a period of at least 6 days | #10 |
The acute psychoactive, autonomic, and endocrine effects of the new psychoactive substance (NPS) 5,6-methylenedioxy-2-aminoindane (MDAI; 3.0 mg/kg, range 180-228 mg) were investigated in six healthy volunteers (four males, two females) in a non-blinded fashion without placebo. Subjective, cardiovascular, and endocrine responses were compared with two different doses of 3,4-methylenedioxymethamphetamine (MDMA) (75 mg and 125 mg) described in previously published placebo-controlled studies, which used identical outcome measures including Visual Analogue Scales (VAS), the Adjective Mood Rating Scale (AMRS), and the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. MDAI was well tolerated and produced subjective effects comparable with those of 125 mg MDMA. MDAI increased blood pressure similar to 125 mg MDMA but did not increase heart rate or body temperature. MDAI increased cortisol and prolactin levels and could be detected in serum about 20 min post ingestion and remained detectable at least for 4 days. In urine, MDAI was detectable over a period of at least 6 days. Further clinical investigations are warranted to assess whether MDAI could serve as drug with medicinal properties.